Instil Bio Q3 2026 Results: Net Loss of $4.23M, Loss Narrows
Instil Bio, Inc. reported a net loss of $13.0 million for the nine months ended September 30, 2026, a significant reduction from the $63.5 million loss in the prior year period. The company is transitioning its strategy, having discontinued its lead product candidate AXN-2510 in January 2026, and is currently seeking to in-license or acquire new therapeutic candidates.
- Key figure
- Net loss $4.23M